142 related articles for article (PubMed ID: 20369749)
1. [Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property].
Piwowar A
Pol Merkur Lekarski; 2010 Feb; 28(164):166-9. PubMed ID: 20369749
[TBL] [Abstract][Full Text] [Related]
2. [Advanced oxidation protein products. Part II. The significance of oxidation protein products in the pathomechanism of diabetes and its complications].
Piwowar A
Pol Merkur Lekarski; 2010 Mar; 28(165):227-30. PubMed ID: 20815174
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background.
Kalousová M; Zima T; Tesar V; Dusilová-Sulková S; Skrha J
Mutat Res; 2005 Nov; 579(1-2):37-46. PubMed ID: 16084533
[TBL] [Abstract][Full Text] [Related]
4. A central role for intermolecular dityrosine cross-linking of fibrinogen in high molecular weight advanced oxidation protein product (AOPP) formation.
Colombo G; Clerici M; Giustarini D; Portinaro N; Badalamenti S; Rossi R; Milzani A; Dalle-Donne I
Biochim Biophys Acta; 2015 Jan; 1850(1):1-12. PubMed ID: 25280629
[TBL] [Abstract][Full Text] [Related]
5. Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy.
Piwowar A; Knapik-Kordecka M; Szczecińska J; Warwas M
Diabetes Metab Res Rev; 2008 Oct; 24(7):549-53. PubMed ID: 18613218
[TBL] [Abstract][Full Text] [Related]
6. [New markers of advanced damage caused by oxidative and carbonyl stress].
Kalousová M; Zima T; Tesar V; Stípek S
Sb Lek; 2001; 102(4):465-72. PubMed ID: 12448197
[TBL] [Abstract][Full Text] [Related]
7. Advanced oxidation protein products as a novel marker of oxidative stress in uremia.
Witko-Sarsat V; Friedlander M; Capeillère-Blandin C; Nguyen-Khoa T; Nguyen AT; Zingraff J; Jungers P; Descamps-Latscha B
Kidney Int; 1996 May; 49(5):1304-13. PubMed ID: 8731095
[TBL] [Abstract][Full Text] [Related]
8. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.
Witko-Sarsat V; Friedlander M; Nguyen Khoa T; Capeillère-Blandin C; Nguyen AT; Canteloup S; Dayer JM; Jungers P; Drüeke T; Descamps-Latscha B
J Immunol; 1998 Sep; 161(5):2524-32. PubMed ID: 9725252
[TBL] [Abstract][Full Text] [Related]
9. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications.
Chawla D; Bansal S; Banerjee BD; Madhu SV; Kalra OP; Tripathi AK
Microvasc Res; 2014 Sep; 95():1-6. PubMed ID: 24984291
[TBL] [Abstract][Full Text] [Related]
10. Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes.
Lalla E; Lamster IB; Schmidt AM
Ann Periodontol; 1998 Jul; 3(1):13-9. PubMed ID: 9722686
[TBL] [Abstract][Full Text] [Related]
11. [Glycoxidative modification of albumin in medical research].
Grzebyk E; Piwowar A
Pol Merkur Lekarski; 2013 Apr; 34(202):239-42. PubMed ID: 23745334
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress and adipocyte biology: focus on the role of AGEs.
Boyer F; Vidot JB; Dubourg AG; Rondeau P; Essop MF; Bourdon E
Oxid Med Cell Longev; 2015; 2015():534873. PubMed ID: 25878764
[TBL] [Abstract][Full Text] [Related]
13. Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients.
Rodríguez-Ayala E; Anderstam B; Suliman ME; Seeberger A; Heimbürger O; Lindholm B; Stenvinkel P
Atherosclerosis; 2005 Jun; 180(2):333-40. PubMed ID: 15910860
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus.
Kalousová M; Skrha J; Zima T
Physiol Res; 2002; 51(6):597-604. PubMed ID: 12511184
[TBL] [Abstract][Full Text] [Related]
15. [Oxidative-antioxidative balance disturbance and risk factors as well as vascular complications in patients with diabetes type 2].
Knapik-Kordecka M; Piwowar A; Warwas M
Wiad Lek; 2007; 60(7-8):329-34. PubMed ID: 18175551
[TBL] [Abstract][Full Text] [Related]
16. Receptor for advanced glycation end-product (RAGE) gene polymorphism 2245G/A is associated with pro-inflammatory, oxidative-glycation markers and sRAGE in diabetic retinopathy.
Ng ZX; Kuppusamy UR; Iqbal T; Chua KH
Gene; 2013 Jun; 521(2):227-33. PubMed ID: 23545311
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD.
Wu L; Ma L; Nicholson LF; Black PN
Respir Med; 2011 Mar; 105(3):329-36. PubMed ID: 21112201
[TBL] [Abstract][Full Text] [Related]
18. Differences in the behavior of advanced glycation end products and advanced oxidation protein products in patients with allergic rhinitis.
Di Lorenzo G; Minciullo PL; Leto-Barone MS; La Piana S; La Porta G; Saija A; Gangemi S
J Investig Allergol Clin Immunol; 2013; 23(2):101-6. PubMed ID: 23654076
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma levels of advanced oxidation protein products (AOPP) as a marker for oxidative stress in patients with active ulcerative colitis.
Alagozlu H; Gorgul A; Bilgihan A; Tuncer C; Unal S
Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):80-5. PubMed ID: 22572519
[TBL] [Abstract][Full Text] [Related]
20. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis.
Miyata T; Hori O; Zhang J; Yan SD; Ferran L; Iida Y; Schmidt AM
J Clin Invest; 1996 Sep; 98(5):1088-94. PubMed ID: 8787669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
